Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gh Research Plc (NQ: GHRS ) 12.60 -0.13 (-1.02%) Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Gh Research Plc < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week May 13, 2024 Via Talk Markets Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May May 05, 2024 We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. Via Talk Markets GHRS Stock Earnings: GH Research Beats EPS for Q1 2024 May 03, 2024 GHRS stock results show that GH Research beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates May 03, 2024 From GH Research PLC Via GlobeNewswire Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week April 23, 2024 A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... Via Talk Markets GH Research: Q4 Earnings Insights February 29, 2024 Via Benzinga Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD April 12, 2024 The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD. Via Talk Markets March Recap: Largest Psychedelic Drug Stocks Up Another 5% March 30, 2024 The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD. Via Talk Markets Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence March 29, 2024 Via Benzinga Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More March 20, 2024 Via Benzinga Topics Economy Exposures Interest Rates Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week March 11, 2024 The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder. Via Talk Markets Exposures Product Safety Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More March 04, 2024 Via Benzinga Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD March 01, 2024 The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%. Via Talk Markets GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates February 29, 2024 Via Benzinga GH Research Reports Full Year 2023 Financial Results and Provides Business Updates February 29, 2024 From GH Research PLC Via GlobeNewswire Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex February 18, 2024 IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking... Via Talk Markets Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More February 15, 2024 Via Benzinga 5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week January 30, 2024 The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. Via Talk Markets Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More January 27, 2024 New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... Via Benzinga Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More January 26, 2024 Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. Via Benzinga GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression January 18, 2024 From GH Research PLC Via GlobeNewswire 5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week January 13, 2024 The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD. Via Talk Markets Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More January 12, 2024 Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD Via Benzinga Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More January 07, 2024 Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Via Benzinga Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development January 04, 2024 Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration... Via Benzinga Psychedelic Stock Gainers And Losers From January 1, 2024 January 01, 2024 Via Benzinga Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More December 27, 2023 President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... Via Benzinga Psychedelic Drug Stocks Index Up In December; Down YTD December 27, 2023 The constituents in the Index are up 9.1% MTD, on average, are down 29.2% YTD, on average, and are now down 85.9% from their highs in 2021. Via Talk Markets Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More December 18, 2023 Biden To Decide On Psychedelic Therapy Bill Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.